Woody is a highly experienced and regarded business development professional with a very successful track record in the healthcare industry. In addition to business development he has been highly involved with strategy, project management, and other key functions within both private and public pharma/biotech companies.
Most recently and prior to joining Immune Regulation, Woody served as Senior Vice President (SVP) of Business Development at UroGen Pharmaceuticals, Inc., where he spearheaded the business development effort to expand its portfolio via in-licensure of a novel immune checkpoint inhibitor that is being developed for treatment of bladder cancer.
Prior to UroGen he served as SVP of Business Development at Sucampo Pharmaceuticals, Inc., where he spearheaded the business development effort for its acquisition by Mallinckrodt Pharmaceuticals for $1.2 billion. Prior to joining Sucampo, Woody’s positions included SVP of Business Development at Lupin Pharmaceuticals, Inc.; VP of Business Development, Licensing at Supernus Pharmaceuticals, Inc., VP of Business Development, Licensing and Project Management at Shire Laboratories; and scientific and business development leadership positions at AAI and Schering Plough.
Woody holds a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, an executive management certificate from the University of North Carolina at Chapel Hill Kenan-Flagler School of Business, and a Bachelor of Science in Zoology from Clemson University.